List of Biologics Companies in United Kingdom - 156

4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.

At Abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That's why we're constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by its lead clinical-stage program, NG-350A, which is being investigated in an ongoing Phase 1 clinical study in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Allergy Therapeutics is a visionary immunology business with specialist experience in the research and development of allergy treatments. We have a well-established commercial presence in Europe and are focused on the US market. We specialise in the diagnosis and treatment of allergy. We mainly sell our products in European countries and our pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, as well as a peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside of allergy are also under evaluation.

At Alliance Pharma plc (AIM: APH) we are a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world. We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. We have previously enhanced our organic growth through selective, complementary acquisitions. Headquartered in Chippenham, UK, we employ around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. Over the last year, Alliance has sharpened its purpose, vision and strategy to align with the stated move towards a predominantly consumer healthcare company, to better position the company for the future, and in response to changing underlying market dynamics. In line with this new strategy, Alliance will focus on the global priority categories of helping damaged skin and supporting healthy aging. Our vision is to be a high performing consumer healthcare company, built on a portfolio of leading, trusted and proven brands. Consumer health products currently deliver 75% of our revenue sales and this continues to be an area of focus going forward. For more information, please visit our website: www.alliancepharmaceuticals.com Adverse Event Reporting Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Pharmacovigilance at Alliance Pharmaceuticals (tel: 01249 466966, email: pharmacovigilance@alliancepharma.co.uk)

AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC). The GTC was founded in 2001 to catalyse the application of pioneering research to gene therapy development and manufacturing related to cystic fibrosis and other respiratory diseases, and originated at Imperial College London and the Universities of Oxford and Edinburgh. AlveoGene has secured an exclusive licence to a proprietary and validated next-generation lentiviral delivery platform developed by the GTC for the treatment of respiratory diseases with high unmet need (excluding the use of the CFTR gene which is mutated in cystic fibrosis). Gene therapies developed using our “InGenuiTy™” platform can be delivered through a nebuliser, transducing lung epithelial cells with high efficiency and producing a long duration of action, and can achieve these effects following repeated administration. The platform has been developed over more than a decade, supported by approximately £72 million in grant funding, including from the Wellcome Trust, Department of Health and Social Care, Medical Research Council and the Cystic Fibrosis Trust.

AMPLY Discovery is a Belfast-based techbio company that deploys machine learning and synthetic biology to mine vast biological data to discover novel drug and nutraceutical candidates. Their technology digitizes life's diversity, using next-gen sequencing for drug discovery to tackle complex diseases such as cancer, metabolic disease, and infectious diseases through AI (artificial intelligence). They have raised over €1.6 million in grant funding from Innovate UK to develop their drug discovery platform.

Amytrx Therapeutics is advancing a new class of peptide therapies to overcome inflammatory diseases—with a vision of providing transformative medicines to patients. Drawing on 25 years of research, Amytrx is harnessing the power of novel anti-inflammatory peptide discoveries to advance new medicines aimed at the prevention and treatment of inflammatory diseases. Our lead therapeutic candidate, AMTX-100, is bioengineered from human protein sequences that modulate the immune system by a natural process, reducing pathogenesis in a range of chronic diseases mediated by excessive inflammation. Joining forces with institutions for clinical research, Amytrx Therapeutics is dedicated to transforming the conventional treatment of chronic inflammatory diseases using biological technology that is easily understood by the human body in a way that is safe, effective, and simple to use.

Antikor is a privately-held biotechnology company originally spun-out from Imperial College. We specialise in the discovery and development of small-format Antibody (Fragment) Drug Conjugates, known as FDCs. FDCs are a form of targeted cytotoxic chemotherapy combining the specificity of antibodies with the potency of small-molecule chemotherapy drugs. Specifically, FDCs are smaller than conventional Antibody Drug Conjugates (ADCs) meaning better tumour penetration and more rapid systemic clearance, potentially leading to a higher clinical therapeutic index. Antikor are developing the next-generation of solid tumour therapies, with a major interest in gastro-intestinal cancers.

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners. Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. For more information, please visit our website at www.apollotherapeutics.com

Arrayjet Ltd is accredited to ISO13485 and providesCRO/CMO liquid handling solutions to support a variety of microarray applications. Their high-speed microarray spotters utilize a patented, non-contact, inkjet technologyfor printing multiplex array-based assays onto slides, Point-Of-Care devices, biochips and microplates.COVID-19: Re-purposed its in-house antibody screening technology to create a population-scale diagnostic program that will help scientists better understand the behavior of the COVID-19 virus and further the rapidity of a global vaccination program.

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

Since 1987, Astrea Bioseparations has been pioneering the design, development and manufacture of affinity purification technology for lab-scale and industrial-scale bioprocessing. With over 25 years experience and success in the development of affinity products and design of new custom adsorbents, Astrea is a world leader in its field. Astrea Bioseparations has sales and support offices in North America and Europe, R&D facilities in Cambridge, UK and manufacturing facilities located on the Isle of Man, British Isles and Joliette, QC, Canada ensuring that we are able to meet your needs and support your application wherever you are. OUR EXPERTISE: • Extensive range of bioseparation products • Custom designed chromatography adsorbents • Over 25 years experience & success • Cost effective solutions • Proven Mimetic Ligand™ technology • Dedicated professional service • Full technical support & in-house training • Experts in adsorbent development & downstream process optimization • Established manufacturing facility (ISO 9001)

aTen Therapeutics is an innovative biotechnology company developing novel therapeutic antibodies to target a fundamental control pathway associated with cancer and several other major diseases. Their technology is focused on antibody discovery and cutting-edge technology development.

Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.

Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms. The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families. Avacta’s proprietary pre|CISIONᵀᴹ targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONᵀᴹ drug candidate, AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic by the second half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.

Barinthus Biotherapeutics plc (formerly Vaccitech plc), a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company’s prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing a COVID-19 vaccine with the University of Oxford, which is approved for use in various territories and licensed worldwide to AstraZeneca through Oxford University Innovation. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.

Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field.

Bastion Therapeutics is a preclinical stage biotechnology company with a mission to develop novel Treg therapies to address the unmet clinical need for inflammatory disorders. We leverage our proprietary GRIT™ platform technology to enhance Tregs to modulate the immune system and overcome challenges associated with previous generations of Treg therapies. Our vision is to provide life-changing therapies that are efficacious, durable and safe to patients suffering from inflammatory disorders.

BBI Solutions - Serving the Science of Diagnostics BBI Solutions is a leading expert in immunoassay development and manufacturing services, and provides an extensive portfolio of products and technologies to the global research and diagnostic markets. The contribution that the BBI Group makes towards achieving this is by adhering to our Mission; ‘To deliver exceptional products and technologies that people rely on to enjoy a better quality of life. Through innovation, partnership, effective delivery and the collaboration of our people, we constantly strive to help set industry standards, engender trust and build our reputation for excellence

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.

Bio Products Laboratory Limited (BPL) is headquartered in Elstree, near London (UK). BPL's mission is to provide a continuous supply of high quality plasma derived products to a growing global market, through investing in the latest research, technology and manufacturing methods, and by ensuring on-going and responsive support to health professionals throughout the world. We are committed to research and development to maintain a key position in a constantly changing market in the 21st century. BPL manufactures a wide range of products from blood plasma. These products fall broadly into three main groups: • Human Albumin Solutions • Human Immunoglobulins • Human Coagulation Factors

Biosceptre is developing a multi-targeted universal CAR-T system, designed to incorporate our nfP2X7 technology, to be capable of treating a range of cancers.

Biotherapy Services Ltd. (BTS) is a pharmaceutical biotechnology company developing and delivering novel autologous therapies for complex and chronic wounds 🥽 🥼. Biotherapy Services, composed of clinicians, technicians, and healthcare managers, was created to bring the most effective platelet-enriching technology to medical practices in the UK and Eire 👩‍🔬 👨‍⚕️. The company has developed proprietary expertise and a unique GMP standard operational service model to provide the RAPID™ Biodynamic Haematogel autologous wound care treatment, targeting complex and chronic wounds such as Diabetic Foot Ulcers and Pressure Sores 🦵️ 🦶️. The RAPID™ Gel harnesses the patient’s own platelets to speed healing, growth, repair, and recovery 🧬️. BTS is currently conducting the RAPID-1 Trial to investigate the efficacy of RAPID™ Gel in wound closure compared to usual and customary care 🔎.

BiVictriX is an emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer. Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues. Thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of the major factors limiting the development of this otherwise promising therapeutic class. BiVictriX's Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links the Company's in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications. The Company's initial focus is on the generation of Bi-Cygni Antibody Drug Conjugates (ADCs), with future plans to expand the technology to other therapeutic modalities (Cell engagers and CAR-T).

Bloomsbury Genetic Therapies ("Bloomsbury") is a clinical-stage biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies. The Company was spun out of University College London and launched in October 2022 with funding from UCL Technology Fund. Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs.

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs

Cambridge Nucleomics is a biotechnology company that specializes in fast and easy RNA measurement at scale with single-molecule accuracy.

Cambridge Research Biochemicals is a biotechnology company that specializes in custom-made peptide and antibody tools.

Maintaining musculoskeletal health is the keystone of overall health as we get older. As we age our physical condition gradually deteriorates, leading to loss of strength, fitness and mobility. In most cases, this isn’t due to a simple decision to stop exercising. It is due to the breakdown of musculoskeletal function caused by disease. Musculoskeletal diseases such as osteoarthritis, tendinopathy and lower back pain are the primary causes of disability and early retirement in people over the age of 65. Currently, there are no approved disease-modifying drugs for these diseases, meaning that physical decline in old age is inevitable. At Causeway, we believe that physical decline in old age is not inevitable and in indeed may be reversible. To address this, we are developing a range of therapies that treat common MSK diseases that will allow us to remain fit and active into our nineties and beyond. Staying active as we get older also reduces the risk of developing osteoporosis, dementia, diabetes, obesity, cancer and cardiovascular disease.

Synthetic biology is changing the way we think about diagnosing and treating microbiome-based diseases. At CC Bio, we harness the power of synthetic biology to engineer and edit the microbiome with surgical precision. Our goal is to eliminate microbiome-based disease in a potent, specific and prophylactic fashion, harmonising the relationship between eukaryotic and microbial cells. By considering the lifestyle needs of our patients, and understanding each microbiome-based disease holistically, we are elevating this fundamental aspect of human health out of the antibiotic era, putting power back in the hands of the consumer.

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company’s preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.

Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system. What we do: Chronos is an Oxford-based biotechnology company operating a semi-virtual R&D model to develop a portfolio of therapies in degenerative and behavioral brain diseases. The team utilises a network of industry- leading contract research organisations to develop NCEs and repurpose existing launched drugs. Chronos also has a dedicated laboratory in Oxford which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen™. Our Focus: - Acquisition, discovery and development of novel proprietary lead candidates. - Repositioning FDA/EMA approved drugs. Targets: - ALS (Lou Gehrig’s Disease) - Other Neurological Diseases - Fatigue - Addictive Behaviour

Cobra Biologics, a Charles River company, is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The team at Cobra's GMP approved facilities has expertise tailored to serving customers around the world; offering a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

Diabetes currently effects over 537 million adults worldwide, with obesity-driven Type 2 Diabetes accounting for over 90% of cases. Dia Beta Labs build on over 30 years of high-impact research from our founding research group at Ulster University to realise the potential of next-generation therapeutics for metabolic disease. It is our goal to impart significant and much-needed change in the management of the global diabetes/obesity crisis.

DIOSVax is a biotech startup working to revolutionise the way humanity protects itself from infectious disease and emerging pathogens. The company is named after its core technology, DIOSynVax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines), a new system that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.

DJS Antibodies acquired by Abbvie (10/20/22) DJS Antibodies was founded upon a vision of creating the next generation of antibody therapeutics. The company is dedicated to developing novel therapeutics to treat chronic inflammatory diseases through the discovery and development of antibodies.

Elasmogen is a therapeutic biologics company developing multi-functional products for difficult-to-treat diseases. The company has built a product pipeline that exploits the advantages of its proprietary, patent protected soloMER technology including first-in-class drug conjugates (SDC) and bi-specific products for the treatment of autoimmune diseases. Our oncology assets include a pipeline of differentiated soloMER-targeted RadioPharmaceutical Therapies (RPT) for the treatment of solid tumour cancers.

Eleven Therapeutics is a biotechnology company leading the AI revolution in nucleic acid therapeutics. They harness the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process.

EmstoPA is a first in class antibody-based reversal agent to treat bleeding caused by tissue plasminogen activator (tPA - Activase®, Alteplase®). tPA is a “clot buster” used to remove the blood clots that cause stroke, pulmonary embolism, and myocardial infarction. In the developed world, tPA is most frequently used to treat acute ischemic stroke where the rates of subsequent intracranial hemorrhage (ICH) are 5-7% . EmstoPA belongs to a class of drugs called anti-fibrinolytics, and and the current market for antifibrinolytics is estimated to be $1,100m /year. Currently no specific tPA reversal agents are in development.

Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover novel cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing database of Dark Antigens that can address the unmet need for cancer-specific targets that are homogenously expressed and highly prevalent in solid tumors. We are advancing multiple approaches to exploit these Dark Antigen targets, with an internal focus on TCR-directed immunotherapies, and additional therapeutic partnerships with Boehringer Ingelheim and another undisclosed global pharmaceutical company.

EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.

Essential Pharma is an international specialty pharmaceutical company dedicated to maintaining access to clinically differentiated, niche medicines in small patient populations. Our high-impact portfolio has a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease, and our products treat patients in more than 70 countries. We are proactive in identifying low volume, difficult-to-manufacture therapeutic products, and late-stage clinical development assets that target rare diseases. We specialise in the acquisition of mature, established, branded medicines that are at risk of shortages or discontinuation, working with partners across the globe to ensure their continued manufacture to the highest standards. Essential Pharma comprises innovative and driven people who are passionate about ensuring continued supply of medicines to patients. We are committed to living by our values – Collaborative, Responsible, Trustworthy and Dynamic – and pride ourselves on our inclusive culture, where everyone's voice is valued and respected. We have an unwavering dedication to employee growth and believe in fostering an environment where all individuals can thrive.

Etcembly’s vision is to decode immune repertoires for health and disease. The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally. We are pushing the frontiers to explore the intersection between immunology and machine learning.

A specialist in computational drug discovery with a focus on developing RNA interference (“RNAi”) therapeutics

Forcefield Therapeutics is a pioneer of best-in-class therapeutics to retain heart function via the protection of cardiomyocytes. Forcefield Tx was founded on the work of Professor Mauro Giacca, an authority in cardiovascular disease and genetic biology and the Heat of the School of Cardiovascular Medicine and Sciences at King’s College London as well as industry experts and investors with a shared purpose to revolutionise treatment following acute myocardial infarction (MI). Forcefield’s unique approach can both retain and protect heart cells, minimising the impact of MI and preventing the cascade of events that may lead to subsequent heart failure. Forcefield Tx is led by a proven team with a record of success from discovery to commercialisation and is backed by a leading FTSE 250 healthcare company, Syncona.

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, streamline their processes, and strengthen their innovation. So when our customers’ potential cures, vaccines, biologics, and accomplishments make strides – or even become new realities for patients – we know our work, our manufacturing expertise, and our partnership helped make it happen. FDB isn’t simply a workplace. It’s a place of passion – a place of what we call Genki. A place where diverse perspectives and people come to life. Where opportunity for growth has no end. Where passion is followed, discovered, and nurtured. Where the energy is undeniable, enthusiasm is pervasive, and drive is infectious. All of our global locations burst with curiosity, inspiration, and extraordinary purpose. So as we continue to grow our teams, our global locations, and our capabilities, Genki will always be our cultural tie. That’s why we’re always looking for passionate, mission-driven people who want to commit their life’s work to enabling better outcomes for patients and their families. For a full listing of jobs that will propel, inspire, and fulfill you, please visit: fujifilmdiosynth.com/careers/ We created this space on LinkedIn to give people a window into work and culture at FDB. We’re highlighting employees’ passion, current openings, and why it’s never been a more exciting time to join FDB.

Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client's projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics. We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.

Genflow Biosciences plc (LON:GENF) (OTCQB:GENFF) is a UK-based biotech company with R&D facilities in Belgium and a U.S. office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results. Managed by an experienced team with decades of experience in the pharmaceutical and biotechnology sectors, the company is optimistic that development programs will continue at pace in the next 24 months.

Glen Clova Scientific Ltd (GCS) is developing a new generation of Active Biologics to treat inflammatory conditions. We are an ambitious spinout from the University of Dundee aiming to address the global need to make effective treatments available for millions of patients. Our novel Virus-Like-Particle technology is poised to address inherent limitations of the current blockbuster class of Biologic drugs. Our vision is to make high end biotech pharmaceuticals much more accessible to patients than current blockbusters. #Glenclovascientific #Dundee

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Discovering and developing innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world.

At Harness Therapeutics we have one mission – physiological upregulation of targets that have the promise to provide disease-modifying therapeutics for neurodegenerative diseases. We use a range of mRNA-targeted oligonucleotide-based methodologies to alter the post-transcriptional regulation of protein synthesis and so increase the target protein in a controlled manner. Our focus on neurodegenerative disease is driven by our passion to develop truly disease-modifying therapies for diseases that affect so many people, yet for which there are few if any therapies that can slow or halt the progression of the disease. The ability to effect controlled increases of protein levels is essential in being able to safely drug targets with narrow therapeutic windows, something that existing platforms cannot achieve. This is critical for neurodegenerative disease as there are now a number of targets that have strong genetic validation linked to disease progression but require controlled increases rather than knock-down or over-expression. Our goal is to open up the target space for neurodegenerative disease and be able to advance effective treatment solutions for the tens of thousands of patients and their families who are facing the certainty of irreversible disease progression, loss of quality of life, and ultimately death. Our name reflects our approach, built and refined since our formation in 2020; harnessing the body’s endogenous cellular processes controlling protein synthesis to achieve controlled increases in protein levels in the safest possible manner. We use our deep expertise in RNA biology/bioinformatics and neuro cell biology to probe the intricate regulation of each target and identify multiple upregulation opportunities. Our multi-year experience focussed on physiological upregulation has allowed us to develop bespoke assays and analytical techniques to screen for constructs that drive small increases in protein, which is a key challenge in this space. Our sole focus on neurodegeneration has allowed us to build deep expertise in the biology of neurons and our targets, and the best possible models for disease – critical in being able to de-risk and translate candidates to the clinic. Neurodegenerative disorders are chronic conditions that destroy parts of the nervous system over time, especially the brain. They result in progressive loss of cognitive and motor function and eventually, death. The most common neurodegenerative diseases include Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis (ALS), Motor neuron disease (MND), Huntington’s disease (HD), Spinal muscular atrophy (SMA), and Spinocerebellar ataxia (SCA). It is estimated that more than 50 million people worldwide are affected by neurodegenerative diseases and this number is increasing as overall life expectancy increases. Most of these conditions are much more likely to happen in people over 65, but some conditions like Huntington’s disease and ALS often appear much earlier.

At ichorbio, we are passionate about animals and believe there is a better way to do in vivo research. For us, the most important consideration was that our antibodies for in vivo use have the lowest possible impact on the animals they are being used in. This is how our mission was born: to create the best antibodies for in vivo research. To achieve our mission, we have created products that have lower endotoxin, higher purity and lower aggregation than other antibodies currently available on the market. Our antibodies adhere to all the same criteria as many of the larger manufacturers from a quality perspective with the added benefit that you can feel confident that you are doing the best for your animals. Best selling antibodies: RMP1-14: https://ichor.bio/ich1132-compared-to-be0146 RMP1-14 LALAPG: https://ichor.bio/revolutionize-your-pd-1-research-with-rmp1-14-lalapg

Ikarovec is a UK-based biotech gene therapy company with a focus in ophthalmology. Ikarovec was originally formed as a spin-out from the biotechnology company.

Iksuda Therapeutics is a biotechnology company focussed on the development of a new generation of antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of non-prodrug/prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform.

ILC Therapeutics (ILCT) is a Scottish-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of hybrid interferon drugs. The company is focused on modulating the Innate Immune System through the development of innovative therapies. ILC Therapeutics has raised significant funding to advance its lead interferon drug candidate and has announced its first international collaboration. The company is dedicated to revolutionizing the treatment of various diseases through its cutting-edge research and development efforts.

Immodulon Therapeutics Limited is a private, clinical-stage, immuno-oncology company dedicated to the development of novel, safe and effective treatments for cancer patients.

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company’s lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

Our vision is to provide the world with the next-generation of therapeutics for unmet medical needs and future threats.

We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.

IngenOx Therapeutics is a clinical-stage Oxford University spinout developing innovative drugs and vaccines aimed at re-invigorating the immune response against cold tumours.

Intima Bioscience - A clinical stage gene and cell therapy company focused on curative intent in solid tumor cancer

IntraBio Ltd., which is a subsidiary of IntraBio Inc, is a private pharmaceutical company located in Oxford, United Kingdom, focusing on the testing and development of novel and repurposed drugs to treat rare neurodegenerative diseases including lysosomal storage disorders.

Isogenica is a bespoke biotech CRO specialised in solving antibody discovery and engineering challenges with small-format antibodies, particularly VHH single-domains. Sometimes known as nanobodies, sdAbs, or heavy-chain single domains, VHHs offer exceptional robustness, flexibility, and manufacturability - , accelerating antibody discovery and development. Their versatility makes them suitable for use in bi-specifics, ADCs, cell and gene therapies, targeted protein degraders, diagnostics and much more. We believe VHHs are the future of medicine - and our synthetic technology gives our VHH libraries the edge in accelerating your drug discovery and development programmes so you can focus on developing the ideas and technologies that could change lives. Offering the largest and most diverse synthetic VHH (nanobody) libraries available on the market, combined with our proprietary CIS display technology, means that VHH discovery with at Isogenica can interrogate up to 1000x more VHH antibody sequences than other display technologies. Our knowledge and experience of VHH, combined with our synthetic libraries’ size and diversity help deliver better antibodies faster, with higher affinity and broader IP coverage. Our in-house experts tailor each project to meet bespoke needs, allowing us to provide industry-disrupting antibody solutions to our partners in around half the time of a traditional animal immunisation campaign. Originally founded near Cambridge, UK over 25 years ago, Isogenica has evolved to become The VHH Company. As an established and trusted antibody partner, our track record of success includes dozens of lead panels including three clinical-stage assets. This bespoke and collaborative approach to antibody discovery extends to how we do business - working flexibly with different partners with uncompromising passion and dedication.

Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of genetically modified MSCs.

Laverock was founded around the core Gene Editing induced Gene Silencing Platform – a step-change in RNAi technology. We fundamentally believe it unlocks the development of next-generation therapeutics through its unique and differentiated properties. We are actively developing a pipeline of GEiGS enabled ex vivo cell therapies, as well in vivo therapeutic approaches.

Leaf Expression Systems is a translational R&D and contract manufacturing business focused on the plant expression of proteins, vaccines, and complex natural products. They use the power of plant-based expression and plant biotechnology to enable their partners to innovate and impact, helping to drive their productivity and create.

Leucid is progressing novel CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers.

Levicept Ltd is a UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. LEVI-04 is currently in a phase II study in patients with osteoarthritis of the knee.

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess.

Lirum Therapeutics is an innovative biopharmaceutical company focused on the treatment of debilitating diseases.

Locate Bio bring together Programmed Drug Release and Instructive Tissue Scaffolds to develop the next generation of products with significant disruptive potential for musculoskeletal conditions.

Macomics is a biotechnology company that focuses on developing precision medicines to modulate macrophages for the treatment of cancer.

Malvern Panalytical is a global leader in the analytics of material and life sciences. We unleash the power of small things to make big things happen for our customers. Our vision is to make the world cleaner, healthier, and more productive. We partner with our customers to make their solutions possible through the power of precision measurements, our expertise, trusted data, and insights. Our people are partners in discovery. We collaborate with our customers and with each other to discover new possibilities and achieve breakthroughs. Our culture is a healthy, high-performance culture shaped by our values: Own it, Aim High and Be True. We’re committed to Net Zero in our own operations by 2030 and in our total value chain by 2040. With over 2300 employees across the globe, we are part of Spectris plc, the world-leading precision measurement group. Malvern Panalytical. We’re BIG on small™

Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused and capital efficient manner. Our journey began back in March 2015 fuelled by the desire to champion high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired three product candidates from Novartis in 2015 and one from AstraZeneca in 2017. Merging with OncoMed in 2019 strengthened our foundation, broadening our reach and adding cutting-edge oncology programs to our pipeline. The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options. Mereo’s agile approach is enabling us to move rigorously but quickly through trial programs. We have taken two therapies from in-licensing to pharma through to Phase 3 studies in under 5 years. Our portfolio covers potential therapies addressing critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and two oncology product candidates. Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across pharma and biotech. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We know what it takes to navigate reimbursement, which can be complex and have the expertise to drive excellence. Follow our updates on this extraordinary journey as we continue to collaborate with our stakeholders to forge new ways of doing things in rare disease.

Mesenbio is a preclinical biopharmaceutical business based at the University of York. Its Cell Line Extracellular Vesicle therapeutic is aimed at delivering next-generation medicine to patients.

Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career.

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

Morvus Technology Limited is a privately owned pharmaceutical company specialising in the discovery and development of novel drugs and diagnostics for the oncology sector. It has offices near Brecon, Wales. Morvus was formed in 2004 after the founders’ previous company, Enact Pharma plc, was acquired. Initially based on the Porton Down Science Park, near Salisbury, in 2007 the company relocated, with considerable assistance from the Welsh Government, to its present site. The company has a diverse portfolio of oncology therapeutics and diagnostics and its lead drug is a potent anti-tumour agent that displays minimal toxicity to normal tissues and is rendered harmless in the circulation. Morvus is developing this drug as a potential treatment for lung cancer using an inhalation route to deliver the drug to tumour sites. The drug is also being assessed as a potential agent to treat some skin cancers.

Myricx Bio is a biotech company headquartered in London, focused on discovering and developing a completely novel class of payloads for antibody drug conjugates (ADCs). They are focused on the discovery and development of a completely novel class of selective cytotoxic payloads for ADCs.

Nanogenics Ltd is a research-based biotechnology company, engages in the development of artificial viruses to deliver gene therapy.

NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours. Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms.

NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising our proprietary ProTide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. For more information, please visit www.orchard-tx.com.

Ori Biotech is a London- and Philadelphia-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, lifesaving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.

Orla Protein Technologies is a leader in Life Science, specializing in recombinant protein design, engineering, and manufacture for surface applications.

OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds. The company is headquartered in the University City Science Center in downtown Philadelphia and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts, UK. Ossianix was founded by Frank S Walsh, Corey Goodman and Lynn Rutkowski who have had distinguished careers in academia, Pharma and Biotech and bring a wealth of experience to the problem of delivering the next generation of Biologics products. The company started operations in 2012 with funding from Lundbeck Pharmaceuticals, BioAdvance and the ALS Association. Current programs focus on neurodegereration, neurooncology, ALS, pain and botulism.

Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).

Oxford Genetics is a synthetic biology company focused on developing novel technologies to overcome challenges associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.

Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a bio-pharma company that was spun out from the University of Oxford’s Department of Oncology and is utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for therapeutic vaccines and diagnostics in cancer and infectious diseases. The technology uses the novel, proprietary platform of ROPs to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other immune oncology (IO) agents. The company has extensive contacts and collaborations in China through Changzhou Bioscience Group (CBIG) that is using the ROP platform for diagnostics in both cancer and in infectious diseases. OVM is developing two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines will be tested as single agents and in combination with IO agents. OVM secured Series A investment from Cancer ROP, a leading South Korean healthcare institution, listed in KOSDAQ, and from existing shareholders in China in 2018. The company is currently seeking Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and also in combination.

“One treatment a year. Life changing.” Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.

Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).

At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”.

PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using this core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.

Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details.

Pneumagen is a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, as an intranasal drug for the prophylaxis of a wide range of viral respiratory tract infections (RTIs). Neumifil is a novel, engineered multivalent Carbohydrate Binding Module (mCBM), which is being developed for the prevention and treatment of Influenza Virus, Respiratory Syncytial Virus, Human Rhinovirus, and Coronavirus infections including SARS-CoV-2 virus. Neumifil acts by binding directly to sialic aid on host cells and preventing the entry of the viral pathogens into the host. Neumifil was generated using Pneumagen’s proprietary GlycoTarge™ technology that identifies novel mCBMs for further development. In addition to Neumifil, Pneumagen is harnessing its GlycoTarge™ platform to develop a pipeline of additional therapies targeting other infectious diseases. Pneumagen was established in 2016 as a spin-out from the University of St Andrews in Scotland giving Pneumagen access to world-class scientific expertise and capabilities in viral RTI’s specifically related to glycobiology.

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.

For when you need it all. We're here. We know scientists give it their all every day to reach their goals. Wherever your research takes you, Proteintech provides all of the antibodies you need to help you do that. All types and forms of antibodies are in stock for your experiment. We’ll be there for every step of your journey. With our GMP capabilities and recombinant custom antibody platform, we can provide the support to scale up from bench to clinic. Search the full catalog at ptglab.com.

Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.

An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.

We are a global, clinical stage pharmaceutical company with a mission to develop and commercialise clinically meaningful, novel therapeutics that will bring life-enhancing benefits to children across the world. Our first development program focuses on Hu14.18, a humanised anti-GD2 monoclonal antibody, licensed from St. Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. A novel key Phase II trial incorporated the addition of Hu14.18 antibody to standard induction chemotherapy and demonstrated outstanding outcomes in patients with newly diagnosed high-risk neuroblastoma, with a 3-year event-free (EFS) and overall survival (OS) of 73.7% and 86.0% respectively. Renaissance Pharma Ltd is led by an Executive Team with extensive experience in the development, approval and commercialisation of oncology and rare disease products. We invite industry manufacturers, formulators, researchers and investors to collaborate with us. Together we can build new partnerships to improve patients' lives. To discuss partnership opportunities, please contact info@renaissancepharma.co.uk We invite industry manufacturers, formulators, researchers & investors to collaborate with us. Together we can build new partnerships to improve patients' lives.

Our focus at ReNeuron is on our CustomEx exosome technology platform, producing exosomes with unique tissue targeting tropisms to deliver a payload of choice to a preferred cell type. Our mission is to partner and develop novel exosome therapeutics for diseases with significant unmet needs.

Resolution Therapeutics is a biotechnology company developing macrophage cell therapy to treat inflammatory organ disease. The company was founded following a productive collaboration between Edinburgh’s Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited. The company is based in the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, and is backed by Syncona. Our initial focus is in chronic liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, only supportive therapies are currently available. For patients with end-stage liver disease (cirrhosis) the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors. At Resolution Therapeutics, we are developing a macrophage cell therapy product to treat patients at risk of liver decompensation, thus helping them avoid the need for a liver transplant.

Rinri Therapeutics is a private biotechnology company developing first-in-class cell therapies to restore hearing. Hearing loss affects 350m people in the world; 90% caused by sensorineural hearing loss (SNHL). There are currently no disease-modifying therapeutics for SNHL patients. Rinri's pioneering technology seeks to reverse SNHL through the regeneration of the damaged sensory cells in the inner ear, the cochlea. Rinri is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield.

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics’ portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of: 1. Midkine antibodies with significant in vivo efficacy and toxicology studies; 2. Midkine RNA therapeutics with novel anti-cancer gene editing action; 3. MK cell therapy with direct and NK-mediated anti-cancer action; and 4. siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

RQ Biotechnology is making instant immunity a reality for vulnerable people. As the leading passive immunization discovery company, we partner with pharmaceutical companies to develop our antibodies into protect against infectious diseases where vaccines cannot. RQ Bio is dedicated to developing medicines based on potent broad-spectrum mAbs to provide instant and long-lasting protection for vulnerable people at risk of severe disease or death from current and future viral infections.

Built for precision, designed for patients. Sania [sah-nee-ah] is a London based biotech company building therapeutics that transform the lives of people with diseases of dysfunctional neural circuits.

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells. At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.

SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST. This breakthrough technology is currently being applied to the world’s most prevalent diseases and infections where earlier and more prevalent diagnoses can make the biggest impact. Founded with the goal of developing PCR accurate point-of-care diagnostics for the world’s most deadly diseases, Senzo Health builds high sensitivity, low-cost, real-time testing technologies. PRICE Laboratory-based diagnostics are expensive, to the individual, the insurer, and the system. By lowering the price of modern diagnostics, we dramatically increase their use and value within healthcare. ACCURACY The Senzo Amplified Lateral Flow test is PCR-accurate. This means that for the first time we can bring testing for a range of new infections and diseases out of the laboratory and closer to the patient enabling a revolution in both diagnostics and treatments. SIMPLICITY Current diagnostics are too complex. From appointments to samples to laboratories to results. By simplifying diagnostics and bringing accurate and real-time testing to the patient, we can save money, save resources and save lives. SPEED Testing is about accurate results. The faster we can return a diagnosis, the sooner we can begin a treatment. Currently, patients and health care professionals often wait days for results. Real-time testing changes this forever, removing the gaps between consultation, testing, data and treatment. ACCESSIBILITY Accurate diagnostics today remain unevenly distributed. The only way to bring testing to patients in lower-income areas is to replace the complex central laboratory model with an affordable point-of-care diagnostics system without sacrificing accuracy.

We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and are maximizing the potential of our technology through research partnerships. Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, we have fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.

Develop safe and effective drug delivery systems for cell andgene therapeutics.

Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care. SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life. Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation. After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds. For more information, you can find our peer-reviewed publications here: Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805 Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079 The importance of our innovative technology has been widely recognised: - Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024 - Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024 - EIC Accelerator Grant (European Innovation Council), 2023 - Life Sciences Innovator (UK Department for Trade and Business), 2023 - EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022 - Winner 2019 URGO Mentorship Programme. Visit us at www.solascure.com

Spirea Limited is a Cambridge-based company created to advance a new generation of antibody-targeted cancer treatments with significantly better efficacy and safety profiles. Spirea will use its innovative technology to enable a pipeline of superior and differentiated antibody drug conjugates for the treatment of a range of solid tumours.

SPOREGEN LIMITED is a biotechnology company based at The London BioScience Innovation Centre (LBIC) in London. SPOREGEN is focused on four areas. 1. Clostridium difficile: we have developed a unique prophylactic and therapeutic approach for C. difficile infection. 2. Probiotics: we identify and develop Bacillus, heat stable, spore probiotic formulations. This includes progression to GRAS status and a number of these have now been licenced including HU58 and HU36. 3. Prophylactic approaches to COVID-19 including SPOR-COV, a unique mucosal immune modulator, and SPORCOVAX, a mucosal vaccine. 4. Contracts: focusing primarily on in vivo evaluations of C. difficile interventions.

SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year.

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak.

Talisman Therapeutics is a human stem cell drug discovery company, based in Cambridge, UK. We are committed to revolutionising the discovery of treatments for Alzheimer’s disease (AD). Our novel human stem cell models of AD provide a transformative platform for rapid and more therapeutically relevant compound identification, thereby offering the potential to significantly accelerate drug discovery and, more importantly, de-risk subsequent development.

A new approach to halting the spread of tau pathology and destruction of nerve cells in the brain Precision immunotherapy for the treatment of tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP)

TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.

T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune & inflammatory conditions. Yet challenges in the identification of therapeutically relevant targets and TCRs has limited the application of such therapies. Our goals: - Develop next generation TCR therapies for treatment of cancer and autoimmune disease - Innovate to make TCR therapies widely available to patients About T-Cypher - Founded in 2021 based on exclusive technology licenses from University of Oxford, and with Oxford Science Enterprises as the major shareholder - Proprietary disease target and TCR discovery platform - Expanding TCR-bank against novel, differentiated targets - Differentiated approach to multiplexing TCRs in therapeutic T-cells - Diverse team with experienced leadership from prominent companies covering cell therapy, gene engineering, immune oncology, autoimmune disease and computational biology

Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately 2 billion people globally. BRIMOCHOL PF has completed its first Phase 3 pivotal trial (BRIO-I) and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and UCL Technology Fund.

STADA Thornton & Ross focuses on a three-pillar strategy consisting of consumer healthcare products, generics, and specialty pharmaceuticals. We’ve been caring for British customers and patients since 1922, and with state-of-the-art manufacturing sites in West Yorkshire and Lancashire, are determined to continue caring for people’s health for generations to come. We are one of UK's leading producers of consumer healthcare products, owning trusted brands such as Covonia, Savlon, Hedrin, Nizoral and Cetraben as well as the cleaning brand Zoflora, which is bought by more than two million households. In keeping with STADA’s global strategy, in the UK we also offer a broad portfolio of branded and generic medicines, across a wide range of therapeutic areas, including dermatology, respiratory, oncology, kidney disease, bone health and many more. With our proven generics and biosimilars, we support a sustainable and cost-efficient NHS, widening patient access to effective treatments. Are you looking for an exciting job opportunity to advance your career in the healthcare industry? Explore our job vacancies: www.thorntonross.com/careers

Tiziana Life Sciences is a dual-listed* (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer related to the liver. Our clinical pipeline includes drug assets for Crohn's Disease, COVID-19 and Progressive Multiple Sclerosis and Hepatocellular Carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience. *Note: Our market cap for TLSA is likely not accurate because its shares are listed on both the London Stock Exchange and the NASDAQ.

TrakCel design, deploy and support digital Cellular Orchestration Solutions that track and manage all the components of the Cell and Gene Therapy supply chain, helping therapy developers to deliver therapies to patients safely and efficiently for both clinical and commercial stage therapies. For each Advance Therapy Patient journey, from sample collection through logistics, manufacturing and final treatment, TrakCel's flagship platform, OCELLOS orchestrates every step, providing a comprehensive chain of custody, chain of identity and traceability throughout. Always remembering there is a patient at the end of everything we do. We innovate. We unite. We transform tomorrow. Want to know more about how TrakCel could transform your therapy supply chain, get in touch and book a free product demo. Join us. See the journey.

Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by our diagnostic tests to respond.

Trio Medicines Ltd (Trio) is a small pharmaceutical company founded in 2005, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO. Here, we focus on developing treatments for rare and unmet medical needs with the aim of improving the health and quality of life of patients around the world. Here at Trio, we are currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).

Tropic Biosciences develops high-performing commercial varieties of tropical crops whichpromote grower well being, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. Some of the products being developed are disease resistant bananas and caffiene-free coffee.

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.

TYG oncology is a biotech company that offers novel cancer immunotherapies based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodulation) technology platform. Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific and controlled immune response against cancer.

VaxEquity is a biotechnology company amplifying the impact of RNA vaccines and therapeutics, through using its next generation self-amplifying RNA (saRNA) platform. The Company uses saRNA to provide greatly enhanced protein expression, combining better tolerability with slower release and thermostability. VaxEquity is pioneering a next generation approach by modifying its saRNA to modulate the immune response and thereby overcoming current limitations. The flexibility of the Company’s platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. VaxEquity was founded in 2020 by Professor Robin Shattock, the Head of Immunology of Infection at Imperial College London and is led by a world class team who are pioneers in the field of RNA.

Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.

Yellowstone aims to unlock a new class of therapeutically targetable frequently expressed antigens with potential to significantly transform patient lives. Spun out of the University of Oxford, Yellowstone is built around the pioneering research of Professor Paresh Vyas, a world-renowned scientific academic, key opinion leader and practising clinician with a specialist focus on acute myeloid leukaemia (AML). The Company is headquartered in Oxford, UK, with backing from a leading FTSE 250 healthcare company, Syncona.